Prime Allied Limited - Aiolos Bio Acquisition at $1.4 Billion Expands GSK Respiratory Portfolio

CENTRAL, Hong Kong - Jan. 11, 2024 - PRLog -- GSK will pay $1 billion immediately, with an extra $400 million connected to success-based regulatory milestone payments, according to a GSK corporate release.

Aiolos was created last year and is headquartered in San Francisco and London. The agreement gives GSK access to AIO-001, a potential best-in-class asthma therapy. Jiangsu Hengrui Pharmaceuticals Co. had granted Aiolos an exclusive license for the therapy outside of China. GSK also announced that Jiangsu Hengrui will receive tiered royalties.

According to GSK, AIO-001 may be injected every six months, providing respite to 315 million asthma sufferers. Following the introduction of a respiratory syncytial virus (RSV) vaccine, the business has expanded its respiratory range. Over the next six years, the business will focus on new products to address the issues of patent expirations and declining income from its core portfolio.

Chief Scientific Officer Tony Wood noted GSK's "proud heritage and deep development expertise" in respiratory therapies, claiming that AIO-001 might benefit 40% of severe asthma patients with low T2 inflammation who still need therapy.

GSK shares rose approximately 0.5% in lunchtime trade in New York on Tuesday. The day's surge added to the stock's 14% gain over the past year.

Prime Allied Limited (https://prime-allied.com) provides asset management and financial consulting. Prime Allied Limited works with you to create a financial strategy that allows you to actively build, conserve, and diversify your assets.